Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2024-06-10 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
8-A12B
Regulatory Filings
2024-06-10 English
Telix Launches Proposed US IPO 2 pages 141.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement by Telix Pharmaceuticals Limited regarding the launch of a proposed initial public offering (IPO) in the United States. It details the offering size, underwriters, listing plans, and legal disclaimers. The content focuses on fundraising and capital market activities, specifically the IPO launch. There are no financial statements, detailed financial performance data, or management discussion of results. The document is not a full financial report, earnings release, or regulatory filing of financial results. It is an announcement about a capital raising event. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7,871 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2024-06-05 English
F-1/A
Regulatory Filings
2024-06-05 English
Telix Completes TLX250-CDx (Zircaix) BLA Submission 3 pages 161.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 3 June 2024. It announces the completion of a Biologics License Application (BLA) submission to the U.S. FDA for a diagnostic imaging agent (TLX250-CDx). The content focuses on the submission event, clinical trial results supporting the submission, and expanded access programs. There are no financial statements, detailed financial analysis, or comprehensive reporting of company performance. The document is a regulatory announcement about a significant corporate event (regulatory submission) rather than a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the submission and clinical data. The document fits best into the category of Regulatory Filings (RNS) as it is a general regulatory announcement about a material event that does not fit other specific categories like earnings release or capital update.
2024-06-02 English
ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS 3 pages 170.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 31 May 2024. It reports positive radiographic progression-free survival (rPFS) data from the ProstACT SELECT trial of their TLX591 rADC therapy candidate in prostate cancer. The content focuses on clinical trial results, safety, efficacy signals, and future trial plans. There are no detailed financial statements, comprehensive management discussion, or full regulatory filings. The document is a corporate announcement of clinical trial data rather than a full financial report, earnings release, or investor presentation. It is not a report publication announcement since it contains substantive data and commentary rather than just a notice of report availability. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial results and company progress that does not fit into other specific categories like earnings release or investor presentation.
2024-05-30 English
Update - Application for quotation of securities - TLX 6 pages 19.0KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the issuance of additional ordinary shares and performance rights, updates to previous announcements, and specifics about the securities to be quoted. The content focuses on share issuance and capital changes rather than financial results, management changes, or other report types. This type of document is typically classified as a Share Issue/Capital Change announcement, as it relates to new share issues and capital structure updates.
2024-05-30 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.